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ABSTRACT
Background: Kentucky ranks first in the US in cancer incidence and mortality. Compounded by
high poverty levels and a high rate of medically uninsured, cancer rates are even worse in
Appalachian Kentucky. Being one of the first states to adopt the Affordable Care Act (ACA)
Medicaid expansion, insurance coverage markedly increased for Kentucky residents. The
purpose of our study was to determine the impact of Medicaid expansion on colorectal cancer
(CRC) screening, diagnosis, and survival in Kentucky.
Study Design: The Kentucky Cabinet for Health and Family Services and the Kentucky Cancer
Registry were queried for individuals (≥20 years) undergoing CRC screening (per US
Preventative Services Task-Force) or diagnosed with primary invasive CRC from January 1,
2011 to December 31, 2016. CRC screening rates, incidence, and survival were compared before
(2011-2013) and after (2014-2016) ACA implementation.
Results: CRC screening was performed in 930,176 individuals and 11,441 new CRCs were
diagnosed from 2011-2016. CRC screening increased substantially for Medicaid patients after
ACA implementation (+230%, p<0.001), with a higher increase of screening among the
Appalachian (+44%) compared with the non-Appalachian (+22%, p<0.01) population. CRC
incidence was increased after ACA implementation in individuals with Medicaid coverage
(+6.7%, p<0.001). Additionally, the proportion of early stage CRC (stage I/II) increased by 9.3%
for Appalachians (p=0.09), while there was little change for non-Appalachians (-1.5%, p=0.60).
CRC survival was improved after ACA implementation (HR=0.73, p<0.01), particularly in the
Appalachian population with Medicaid Coverage.
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Conclusions: Implementation of Medicaid expansion led to a significant increase in CRC
screening, CRC diagnoses, and overall survival in CRC patients with Medicaid, with an even
more profound impact in the Appalachian population.

KEYWORDS: Medicaid expansion; Appalachia Kentucky; colorectal cancer

Abbreviations:
CRC: Colorectal cancer
ACA: Affordable Care Act
FPL: Federal Poverty Level
KHFS: Kentucky Cabinet for Health and Family Services
KCR: Kentucky Cancer Registry

5

INTRODUCTION
Kentucky ranks first nationally in incidence and mortality of all site cancers.1,2 The Appalachian
region of Kentucky heavily contributes to these poor outcomes, where cancer surpasses heart
disease as the leading cause of death.2,3 The etiology of the disproportionately high cancer rate is
multifaceted, but a major factor is the distressed socioeconomic status in Kentucky.2 For the past
decade, Kentucky maintained the fifth highest poverty rate in the nation.4 Even worse,
Appalachian Kentucky has the highest poverty rate in the nation at an astounding 1.7 times the
national average. Of the 54 counties in Appalachia, 38 counties are economically distressed, or
ranks in the bottom 10% of all US counties.5
High poverty levels left a large portion of the Kentucky population uninsured and subsequently
unable to seek preventative care.2,6-8 The Medicaid Expansion of the Patient Protection and
Affordable Care Act (ACA) was incredibly successful in reducing the uninsured rate in
Kentucky.9 The expansion, enacted in 2014, provided Medicaid coverage to those at 138% of the
federal poverty level (FPL). Being one of the first two states to implement ACA, uninsured rates
dropped in Kentucky by more than half from 13.6% pre-ACA to 6.1% two years post-ACA. At
the same time, the national uninsured rate dropped from 14.7% to 9.4%. Medicaid Expansion in
the neighboring state of Illinois had a slightly smaller impact; its uninsured rate dropped from
12.9% to 7.0%. Conversely, Tennessee, a state that did not expand Medicaid, experienced a
modest decrease in the uninsured rate (from 13.8% to 10.2%). The population most impacted by
the expansion of Medicaid was those under 138% of national poverty level, which demonstrated
a nearly threefold drop in the rate of uninsured individuals (from 25.0% to 9.4%).10
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When looking specifically at colorectal cancer (CRC), Kentucky ranks first nationwide for
incidence (50.0 cases per 100,000) and fifth for mortality (17.2 deaths per 100,000).1,2 As
expected, Appalachian Kentucky has even higher incidence (55.1 cases per 100,000) and
mortality (20.2 deaths per 100,000).2 Screening for CRC has been demonstrated to significantly
decrease incidence and mortality.11,12 The US Preventative Services Task Force recommended
screening for those beginning at the age of 50, with one of the following tests: high-sensitivity
fecal occult blood testing annually, sigmoidoscopy every 5 years, or colonoscopy every 10
years.13 In the past, Kentucky has reported low rates of CRC screening. In 1999, only 34.7% of
the Kentucky population received CRC screening of any type, ranking 49th in the nation.14 These
results prompted several state-wide screening initiatives including the establishment of the
Kentucky Colon Cancer Screening Program and the Kentucky Colon Cancer Screening Advisory
Committee in 2002. As a result, CRC screening rates improved to 65.9% in those 50 years or
older in 2012. However, CRC screening rates, although improved in western and central
Kentucky, remained low in eastern Appalachian Kentucky.15,16 The purpose of this study is to
evaluate the effect of ACA Medicaid expansion on CRC screening, incidence, and survival in the
Kentucky population with a particular focus on Appalachian Kentucky.
METHODS
Data Sources

Kentucky CRC screening, incidence and outcomes data were obtained from two distinct
databases. CRC screening data was obtained from the Kentucky Hospital Discharge Database,
which resided in the Kentucky Cabinet for Health and Family Services (KHFS). Ethical approval
for the utilization of this database was obtained from the University of Kentucky’s Office of
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Research Integrity Institutional Review Board. The sample population included all patients older
than 20 years old who underwent CRC screening from January 1, 2011 to December 31, 2016.
Each screening occurrence was captured through the CPT code involving either screening or
diagnostic colonoscopy, sigmoidoscopy, guaiac based fecal occult test, fecal immunochemical
test or fecal DNA test. Each case was then confirmed with the ICD (9 and 10) code for screening
visits, allowing for the capture of recoded endoscopic procedures from screening to diagnostic
due to positive findings.
CRC demographics, incidence, and cancer outcomes data in the state of Kentucky were obtained
through the Institutional Review Board approved collaboration with the Kentucky Cancer
Registry (KCR). A data use agreement was obtained between the investigator and KCR in April
2018. The KCR is a population-based registry and has been awarded the highest level of
certification by the North American Association of Central Cancer Registries for an objective
evaluation of completeness, accuracy and timeliness every year since 1997. In addition, KCR is a
National Cancer Institute Surveillance, Epidemiology, and End Results population-based cancer
registry. The KCR also links its database annually with the State Death Certificate data and
National Death Index to capture the most accurate survival information.17 The study population
included all patients 20 years and older, who were diagnosed with CRC between January 1, 2011
and December 31, 2016. Only the first invasive primary CRC was included in the analysis. Cases
that were captured through autopsy or death certificates were excluded. Measures obtained
include demographics (age at diagnosis, sex, race, metropolitan status, Appalachian status) and
insurance coverage (Medicaid, Medicare, other public insurance, private insurance and no
insurance) based on payer information at the time of diagnosis from the KCR. Other variables of
interest such as socioeconomics (percentage below poverty status at the county level, high school
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education ascertainment at the county level) and clinical information (tumor grade, stage at
diagnosis and survival) were also included in the data analysis.
For the purpose of this study, the post-ACA implementation time period was defined as the
implementation of Medicaid expansion on January 1, 2014, to December 31, 2016. The pre-ACA
period was defined as an equal length of time before ACA implementation from January 1, 2011
to December 31, 2013. County of residence at time of discharge from the KHFS or time of
diagnosis from the KCR were used to define patient’s geographic regions. Metropolitan status
was based on the 2013 Urban-Rural Continuum codes with the values of 1-3 as urban and 4-9 as
rural.18 The county-level Appalachian status was defined according to the Appalachia Regional
Commission, as the 54 counties in Eastern Kentucky.5 The 2008-2012 American Community
Survey was used to create the poverty status and high school education ascertainment variables,
which were collapsed into four levels based on the quartiles of their distributions. Poverty status
is categorized as: low (<16.2%), moderate (16.2-18.1%), high (18.2-21.7%), very high
(>21.7%); education ascertainment is categorized as: very low (<75.8%), low (75.8-84.3%),
moderate (84.4-88.0%), and high (88.1-91.8%). Stage at diagnosis was also categorized as early
(Stage I and II) and late stage (Stage III and IV). Survival was defined as length of time from
date of diagnosis to death or end of the study period.
Statistical Analysis
Descriptive analysis was conducted for all variables. Chi squared tests were performed to
examine the association between ACA status and other covariates, stratified by insurance status.
Kaplan-Meier plots and Log-Rank tests were conducted by ACA status for each insurance type
separately. Cox regression analysis was performed to determine whether ACA status is
associated with survival while controlling for other variables, Goodness of fit and proportional
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hazard assumption were examined. Analyses were two-sided with a p-value ≤ 0.05 used to
identify statistical significance. All analyses were performed using SAS Statistical Software
version 9.4 (SAS Institute, Inc., Cary, North Carolina, USA).

RESULTS

Patient characteristics
A total of 930,176 patients were screened for CRC from 2011 to 2016. The highest proportion of
patients screened was in 2015, and the lowest proportion screened was in 2011 (Table 1). As
expected, the highest proportion of those screened were in the age 51-65 group. Interestingly,
8.2% of those screened were younger than 40 years old, which may be secondary to the high
incidence of familial causes of CRC in Kentucky.19 More females were screened than males. The
majority of patients who received screening were white (92.7%) and a small proportion were
black (6.0%), which is slightly lower than the overall percentage of black patients in Kentucky
(8.4%) demonstrating a screening disparity.20 When looking at insurance coverage, nearly half of
those screened had private insurance (47.8%), while 9.7% of patients had Medicaid and 1.4%
were uninsured. About a fourth of the patients who received screening were Appalachian. When
looking specifically at the Medicaid subgroup, higher proportion of female (62.6%) and black
patients (9.6%) received screening compared to all insurance types. Nearly half of the Medicaid
patients who received screening were Appalachian (42.3%).
Impact of ACA Expansion on CRC Screening
A total of 408,500 patients were screened pre-ACA and 521,676 were screened after ACA
implementation, an increase of 27.7% (Table 2). Colonoscopy was utilized as the major
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screening method in 72.7% of patients. The 51-65 age group had the highest increase in
screening, while both sexes increased proportionally. When comparing screening rates based on
insurance coverage, patients with Medicaid demonstrated the highest increase in CRC screening.
A total of 69,328 Medicaid patients received screening after ACA implementation compared to
20,980 individuals who were screened pre-ACA, thus representing an increase of 230%.
Screening rates for patients with private insurance increased by 10.2% and Medicare patients
increased by 29.9%. Overall, 43.7% more Appalachian patients received CRC screening after
ACA implementation compared to pre-ACA.
When looking specifically at Medicaid patients, individuals in the 51-65 age group had the
highest improvement in screening (+292.5%). There was also a higher proportional increase in
screening in males compared to females after ACA implementation. The increase of coverage in
all races remained proportional. Similar to the overall Kentucky trend, Medicaid coverage of
Appalachian patients increased by 199.0% while uninsured Appalachian patients decreased by
77.7% after ACA implementation (Figure 1).

Impact of ACA Expansion on CRC Incidence

From January 1, 2011 to December 31, 2016, 11,441 Kentucky patients were diagnosed
with CRC. After ACA Medicaid expansion, there was not a significant increase in incidence
(5,665 pre-ACA vs. 5,776 after ACA implementation), but there was a change in the distribution
(Table 3). The CRC incidence in the 20-49 age group increased by 22.8%, while the age 75-90
group decreased by 7.5%, indicating a shift toward an increase in incidence in the younger
population consistent with national CRC trends.21 When separated by insurance, the proportion
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of Medicaid patients who were diagnosed with CRC increased by 132.4% after Medicaid
expansion. In patients who had Medicaid, there were no significant differences in regard to
poverty and education level indicating a similar population before and after ACA
implementation. Consequently, there was a four-fold decrease in incidence in the uninsured
group.
When evaluating patients who had Medicaid coverage, there was an increase in Appalachian
CRC incidence (87.8%) (Figure 2). When separating out incidence by stage in this group, the
proportion of early stage diagnoses (stage I/II) increased by 9.3% for Appalachians (p=0.09),
which was not noted in non-Appalachians (-1.5%, p=0.60). There was no effect on late stage
diagnosis.

Impact of ACA Expansion on CRC Survival
When evaluating the role of ACA expansion in CRC survival, both Medicaid and
Appalachian patients benefited while uninsured patients suffered. After ACA implementation,
Medicaid patients exhibited improved survival compared to patients prior to instituting ACA
(Figure 3). Conversely, the remaining uninsured patients who did not receive coverage from
ACA implementation had a worse survival compared to pre-ACA implementation. There were
no significant differences in survival for private insurance and Medicare with regards to ACA
expansion. Notably, the survival differences after ACA implementation was evident in Medicaid
patients after the first year and increased each year thereafter (eTable 1). We noted an overall
worse survival (HR 2.12, 95%, CI 1.23-3.67, p = 0.048) in the black uninsured population
compared with the white population, consistent with national trends.22 This effect was not seen in
any other insurance groups.
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When controlling for age, sex, race, cancer stage and grade, cox regression analysis revealed all
Medicaid patients had improved survival after ACA implementation compared to pre-ACA
implementation (HR 0.73, 95% CI 0.58-2.11; p = 0.008). Interestingly, when looking specifically
at Appalachian patients with Medicaid coverage, there was significantly improved survival after
ACA implementation compared to the period pre-ACA (Figure 4). However, there was no
difference in survival in the Medicaid non-Appalachian population, indicating the improvement
in overall Medicaid patient survival after ACA implementation was heavily contributed by the
Appalachian population.

DISCUSSION

ACA Medicaid expansion has had unprecedented success in providing Medicaid coverage for the
uninsured population in Kentucky. Earlier studies demonstrated implementation of the expansion
increased screening in prostate cancer,23 cervical cancer,24-26 and breast cancer.25,27 In Kentucky,
improved coverage was also associated with earlier diagnosis of breast cancer and improved
treatment quality.27 We set out to evaluate the impact of ACA expansion on CRC screening. We
found the expansion of Medicaid in Kentucky significantly increased CRC screening,
particularly in the Appalachian population. Moreover, ACA expansion was associated with
increased CRC incidence in the Medicaid population with a shift toward early stage diagnosis in
Appalachian patients. Importantly, we demonstrated for the first time that ACA expansion
significantly increased CRC survival in both the Medicaid and Kentucky Appalachian
populations.
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Our study established the substantial impact of insurance coverage in amplifying CRC screening.
Over the past two decades, Kentucky has implemented several programs to expand CRC
screening.15 The major barriers to CRC screening include lack of insurance coverage and lack of
provider recommendation.6-8,28,29 Our study demonstrated the ACA Medicaid expansion
decreased the number of low-income uninsured patients in Kentucky which help to alleviate
barriers to healthcare access. By 2015, in the second year of expansion, there was 12% increased
access to PCPs, allowing greater than 85% of low-income patients to easily obtain physician
visits.30 Improved healthcare system contact led to increased preventative screening by enabling
access to PCPs.9 The Behavioral Risk Factor Surveillance System reported in 1999 the CRC
screening rate in Kentucky was 34.7% compared to 43.9% nationally. CRC screening plateaued
just before ACA implementation at 65.7%. After ACA implementation in 2014, screening in
Kentucky further increased to 69.6% compared to 66.6% nationally.14,31 However, Appalachian
Kentucky screening lagged behind, at 63.0%.2 The most recent 2016 data revealed further
improvement of screening rates to 70.1% compared to 67.7% nationally.14,31 Similarly, we
identified a more than threefold increase in CRC screening three years after Medicaid expansion.
In Kentucky, additional insurance coverage increased CRC incidence immediately after ACA
implementation. CRC incidence has steadily decreased over the past 40 years.32,33
Microsimulation models suggest the largest contribution come from screening, while risk factor
reduction and treatment improvements are minor contributors.33,34 Early detection of precursor
lesions would have immediate reduction of CRC incidence within the first two years and
maximal reduction by 15 years.32,34-38 We would expect immediate increased incidence in newly
insured Medicaid patients as existing cancers are identified. In addition, this population may also
have a shift toward earlier stage diagnosis.39,40 However, as expected, the removal of pre-
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cancerous lesions would decrease cancer progression leading to decreased incidence rates.11
Similarly, we identified an increase of incidence in the Medicaid and Appalachian population
immediately after ACA implementation. We demonstrated a trend toward higher rates of early
stage (I and II) CRC diagnosis in the Appalachian population, which was not seen in the
uninsured population. Because this study evaluated the short-term effects of Medicaid expansion,
we would not expect a decrease in CRC incidence.
CRC screening is very effective in reducing the cancer specific mortality risk. Zauber et al12
demonstrated a 53% reduction of 10-year survival in patients who received a screening
colonoscopy. In fact, the impact of CRC screening on survival continues for up to two decades.41
Even so, CRC mortality in Kentucky remain behind national standards. In 2011-2015 the
mortality rate of CRC nationally was 14.5 per 100,000 compared to 17.0 per 100,000 in the state
of Kentucky.2 Appalachian Kentucky mortality was even higher, with a more profound benefit
from screening.42,43 In just a short time interval After ACA implementation, we showed that
Medicaid patients had a 27% lower risk of death compared to pre-ACA, while those who were
uninsured had an overall worse survival. Notably, the Kentucky Appalachian patients also had a
significantly improved survival associated with the dramatic expansion of Medicaid coverage as
a result of increased CRC screening.
We demonstrated a markedly improved survival in both the Medicaid and Kentucky Appalachian
population in just a short time after ACA implementation. In fact, the significant survival
improvement was evident within the first year. Similarly, several studies including a large
metanalysis demonstrated a survival difference at 3 years after receiving CRC screening, with
the maximal effect at 15 years.44,45 The short term effects of a CRC screening program
implementation on survival was also found in a Kaiser Permanente health system demonstrating
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a significant decrease in mortality within 4 years.11 Our survival follow-up time was greater than
6 years for the pre-ACA group and greater than 4 years for the after ACA implementation group.
As CRC incidence can drop within two years after improved screening, survival differences can
be seen within our follow up time period partly due to early detection and treatment.35
Importantly, the improved survival after ACA implementation was not evident in the private,
Medicare and uninsured populations, indicating the specific association of survival after CRC
screening with Medicaid patients.
The results of this study could be generalized to other states that have expanded Medicaid
coverage. Nonetheless, there are several limitations to our current study. The CRC screening data
may contain a small number of patients who underwent more than one screening procedure, thus
was counted twice. However, it is extremely unlikely for a second procedure to be coded as a
screening procedure, and more likely to be coded as a diagnostic procedure. In addition, prior to
2016, post-hoc manipulation of CPT codes was legal. As a result, there may be a bias among the
colonoscopies that had CPT codes converted from screening to diagnostic as a result of a
positive finding during the procedure. This would have underestimated screening colonoscopies
before 2016. Next, the significant survival benefit identified in the Medicaid population after
ACA implementation may be contributed by other factors which were not included in the
analysis. For example, prior to ACA implementation, only the most impoverished adults (less
than half of FPL) were covered by Medicaid, whereas after implementation, the coverage
included up to 138% of the FPL. This higher income group were likely more health conscious
and had better access to care, which was evident by the decreased survival in the uninsured
population, suggesting only patients with the lowest level of access remain uninsured after ACA
implementation. However, these individual socioeconomic and health access factors were not
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available for the data analysis. Lastly, cancer survival is also related to reliable quality treatment,
which is not accounted in our survival analysis. However, due to our demonstration of
improvement in survival post-ACA, poor quality treatment would unlikely effect our results
negatively.

CONCLUSIONS
CRC incidence and mortality in Kentucky is one of the highest in the United States. ACA
Medicaid expansion has positively affected insurance coverage in this population leading to
improved CRC screening and improved short-term survival. Future long-term survival studies
are needed, but the short-term benefits of the ACA expansion have bridged a gap in CRC
disparities in Kentucky.
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Table 1. Patient Demographics.
n

%

Pre-ACA*

408,500

43.9

Post-ACA

521,676

56.1

2011

124,049

13.3

2012

142,166

15.3

2013

142,285

15.3

2014

151,956

16.3

2015

194,406

20.9

2016

175,314

18.9

20-40 y

75,923

8.2

41-50 y

129,050

51-65 y

422,588

66-70 y

118,714

>71 y

183,901

19.8

Female

517,830

55.7

Male

412,346

44.3

White

862,144

92.7

Black

55,742

Other

12,290

1.3

Not Insured

14,064

1.5

Private

444,794

Medicare

367,974

Medicaid

90,308

Other public†

13,036

1.4

I

2,444

21.8

II

2,600

III

2,789

IV

2,224

Unknown

1,152

10.3

682,545

73.4

Patient characteristic
All Kentucky patients, 2011-2016, n = 930,176
ACA Status

Year screened

Age

Sex

Race

Insurance

Stage

Appalachian Status
Non-Appalachian

13.9
45.4
12.8

6.0

47.8
39.6
9.7

23.2
24.9
19.8

23
247,631

26.6

Pre-ACA*

20,980

23.2

Post-ACA

69,328

76.8

2011

6,606

733

2012

7,282

8.1

2013

7,092

7.8

2014

20,394

22.6

2015

27,772 (30.8%)

30.8

2016

21,162 (23.4%)

23.4

20-40 y

19,762

21.9

41-50 y

21,052

51-65 y

48,151

66-70 y

664

>71 y

679

0.8

Female

56,510

62.6

Male

33,798

37.4

White

79,798

88.4

Black

8,661

Other

1,849

2.0

Non-Appalachian

52,112

57.7

Appalachian

38,196

42.3

I

195

19.7

II

207

III

237

IV

255

Unknown

95

Appalachian
Medicaid patients only, 2011-2016, n = 90,308
ACA Status

Year screened

Age

Sex

Race

Appalachian Status

Stage

*Pre-Affordable Care Act (ACA) from 2011 to 2013, post-ACA from 2014-2016.
†Includes

TRICARE, Veterans Affairs, and Military insurances.

23.3
53.3
0.7

9.6

20.9
24.0
25.8
9.6
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Table 2. Bivariate Analysis of Pre-Affordable Care Act and Post-Affordable Care Act of
Colorectal Cancer Screening
Colorectal cancer screening, n (%)
Patient
characteristic

Pre-ACA*, n = 408,500

Post-ACA, n = 521,676

Age

p Value
< 0.0001

20-40 y

36,002 (8.8)

39,921 (7.7)

41-50 y

59,825 (14.7)

69,225 (13.3)

51-65 y

182,362 (44.6)

240,226 (46.0)

66-70 y

50,355 (12.3)

68,359 (13.1)

>71 y

79,956 (19.6)

103,945 (19.9)

Sex

< 0.0001
Female

228,830 (56.0)

289,000 (55.4)

Male

179,670 (44.0)

232,676 (44.6)

Race

< 0.0001
White

379,190 (93)

482,954 (93)

Black

23,817 (6)

39,125 (6)

Other

5,493 (1)

6,797 (1)

10,617 (2.6)

3,447 (0.7)

Private

211,618 (51.8)

233,176 (44.7)

Medicare

160,027 (39.2)

207,947 (39.8)

Medicaid

20,980 (5.1)

69,328 (13.3)

5,258 (1.3)

7,778 (1.5)

Insurance

< 0.0001

Uninsured

Other

public†

Appalachian status

< 0.0001

No

306,880 (75.1)

375,665 (72.0)

Yes

101,620 (24.9)

146,011 (28.0)

*Pre-Affordable Care Act (ACA) from 2011 to 2013, post-ACA from 2014-2016.
†Includes

TRICARE, Veterans Affairs, and Military insurances.
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Table 3. Bivariate Analysis of Pre-Affordable Care Act and Post-Affordable Care Act of
Colorectal Cancer Incidence Separated by All Insurance Types and Medicaid Only.

Patient
characteristic

Pre-ACA* (n = 5,665), n (%)

Post-ACA (n = 5,776), n (%)

p Value

All insurance types
< 0.001

Age
20-49 y

648 (11.4)

796 (13.8)

50-64 y

2,005 (35.4)

2,072 (35.9)

65-74 y

1,456 (25.7)

1,468 (25.4)

≥75 y

1,556 (27.5)

1,440 (24.9)
0.915

Sex
Female

2,641 (46.6)

2,687 (46.5)

Male

3,024 (53.4)

3,089 (53.5)
0.007

Race
White

5,237 (92.4)

5,302 (91.8)

Black

365 (6.5)

368 (6.4)

Other

63 (1.1)

106 (1.8)
< 0.001

Insurance
Uninsured

310 (5.5)

67 (1.2)

Private

1,788 (31.5)

1,810 (31.3)

Medicare

3,001 (53.0)

2,964 (51.3)

Medicaid

299 (5.3)

695 (12.0)

267 (5.7)

240 (4.2)

Other

Public†

0.131

Appalachian status
No

3,888 (68.6)

3,888 (67.3)

Yes

1,777 (31.4)

1,888 (32.7)

Tumor grade
Welldifferentiated
Moderatelydifferentiated
Poorlydifferentiated
Undifferentiate
d
Unknown
Medicaid only

< 0.001
265 (4.7)

437 (7.6)

3731 (65.9)

3735 (64.6)

424 (7.5)

439 (7.6)

466 (8.2)

425 (7.4)

779 (13.7)

740 (12.8)

Age
20-49 y

0.003
78 (26.1)

220 (31.7)

26
50-64 y

183 (61.1)

433 (62.3)

65-74 y

19 (6.4)

23 (3.3)

75-90 y

19 (6.4)

19 (2.7)

Sex

0.059

Female

152 (50.8)

308 (44.3)

Male

147 (49.2)

387 (55.7)

Race

0.633

White

268 (89.6)

603 (86.8)

Black

28 (9.4)

83 (11.9)

Other

3 (1.0)

9 (1.3)

Appalachian status
No
Yes
Poverty

0.008
160 (53.5)

434 (62.5)

139 (46.5)

261 (37.5)

level‡

0.072

Low

51 (17.1)

148 (21.3)

Moderate

62 (20.7)

166 (23.9)

High

72 (24.1)

172 (24.7)

114 (38.1)

209 (30.1)

Very High
High school

education§

0.084

Very Low

121 (40.5)

217 (31.2)

Low

69 (23.1)

167 (24.0)

Moderate

85 (28.4)

237 (34.1)

High

24 (8.0)

74 (10.7)

*Pre-Affordable Care Act (ACA) from 2011 to 2013, post-ACA from 2014-2016.
†Includes
‡Low,

TRICARE, Veterans Affairs, and Military insurances.

% under poverty level ≤ 16.2; Moderate, % under poverty level 16.3-18.1; High, % under poverty level 18.2-

21.7; Very High, % under poverty level ≥ 21.8.
§Very

Low, % completed high school ≤75.8; Low, % completed high school 75.9-84.4; Moderate, % completed high

school 84.5-88.1; High, % completed high school ≥88.2.
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FIGURE LEGENDS:
Figure 1. Colorectal cancer (CRC) screening by insurance and Appalachian (App) status. CRC
screening data were obtained from Kentucky Cabinet for Health and Family Services from
January 1, 2011 to December 31, 2016. (A) All screening cases were separated by insurance
status depending on pre-Affordable Care Act (ACA) (screening obtained in 2011 to 2013) or
post-ACA status (screening obtained in 2013-2016). (B) Patients with Medicaid coverage who
received screening were separated by Appalachian and non-Appalachian status and compared
pre- and post-ACA implementation.

Figure 2. Colorectal cancer (CRC) incidence by insurance and Appalachian (App) status. CRC
incidence from January 1, 2011 to December 31, 2016 was obtained from the Kentucky Cancer
Registry. Pre-ACA was defined as the time period from 2011 to 2013 while post-ACA was from
2014 to 2016. (A) All cases of CRC were separated out by insurance types and compared before
and after ACA implementation. (B) Incidence rates of CRC were compared in all Medicaid
patients separated by Appalachian and non-Appalachian status.

Figure 3. Colorectal cancer (CRC) survival after Affordable Care Act (ACA) by insurance type.
Survival analysis was performed via Kaplan Meier plots. Pre-ACA was defined as the time
period between 2011 and 2013, and post-ACA was defined as the time period between 2014 and
2016. All CRC cases were separated by insurance status: (A) private; (B) Medicaid; (C)
Medicare; and (D) no insurance.
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Figure 4. Colorectal cancer (CRC) survival for Medicaid patients after Affordable Care Act
(ACA) by Appalachian status. Medicaid patients who were diagnosed with CRC were identified
in the Kentucky Cancer Registry from January 1, 2011 to December 31, 2016. Survival analysis
was performed with Kaplan Meier plots to evaluate survival in the (A) non-Appalachian and (B)
Appalachian population.
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Precis
Kentucky was an early adopter of the Affordable Care Act Medicaid Expansion, providing a
significant amount of insurance coverage for poor individuals. As a result, Kentucky had
increased colorectal cancer screening, earlier diagnosis, and improved survival, especially
evident in Medicaid and Appalachian patients.

